ArticleJournal of hepatocellular carcinoma2026
Baseline ALBI Grade as an Independent Prognostic Factor of Survival in High-Risk Real-World HCC Under Atezolizumab-Bevacizumab.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Atezolizumab plus bevacizumab is the current first-line standard for unresectable hepatocellular carcinoma (HCC). However, real-world populations often differ substantially from clinical trials particularly in terms of hepatic reserve and tumor burden. We aimed to evaluate survival outcomes and hepatic functional changes in a real-world cohort, specifically focusing on the prognostic role of baseline ALBI grade and portal vein tumor thrombosis (PVTT). Methods: This multicenter retrospective cohort study analyzed 43 patients with BCLC-B/C unresectable HCC treated between January 2022 and June 2025. Tumor response was assessed according to mRECIST. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Cox regression analyses were performed to identify independent prognostic factors. Results: The cohort was characterized by advanced disease (72.1% BCLC-C stage, 74.5% ALBI grade ≥2, and 41.9% PVTT). Median OS and PFS were 9.5 months (95% CI, 6.5-12.4) and 6 months (95% CI, 3.8-8.2), respectively. Patients with ALBI grade 1 had significantly longer OS compared to those with ALBI ≥2 (21 vs 8 months; p=0.018). In multivariable Cox regression analysis, higher baseline ALBI grade was independently associated with shorter OS (HR 3.1, 95% CI 1.1-8.3; p=0.027) and PFS (HR 2.8, 95% CI 1.2-6.9; p=0.021). Hepatic decompensation occurred in 41.9% of patients and was associated with deterioration in liver function scores. Conclusion: In this high-risk real-world cohort of patients with HCC treated with atezolizumab plus bevacizumab, baseline ALBI grade was independently associated with poorer survival outcomes, suggesting that hepatic functional reserve may be important for prognostic stratification. Larger prospective studies are needed to clarify the relative prognostic contributions of ALBI grade and tumor-related factors such as PVTT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.